Recursive Adaptation - Addiction Medicine and Policy

Recursive Adaptation - Addiction Medicine and Policy

Home
CASPR.org
Archive
About

March 2025

February 2025

Semaglutide compounding is being shut down– can a gummies hack keep it alive?
And will patients turn on Trump and RFK as hundreds of thousands lose access to GLP-1s?
 • 
Nicholas Reville
1
New discussion list for SUD professionals working with GLP-1s
Be in touch if you would like to join.
 • 
Nicholas Reville
Ozempic (semaglutide) shows huge reductions in high-risk heavy drinking, in first-ever clinical trial
Powerful findings in Christian Hendershot's RCT w/ 48 non-treatment seekers and relatively low doses of semaglutide.
 • 
Nicholas Reville
4
Suzetrigine approved, AUD endpoints might be updated?, and more addiction news
Has the FDA already updated AUD qualified endpoints but can't say so yet?
 • 
Nicholas Reville
One of the most important GLP-1 for addiction trials has just begun (and needs another site)
Sue Grigson's trial is looking at semaglutide for OUD-- and they urgently need support to add more patients.
 • 
Nicholas Reville
1

January 2025

Don't let your dentist give you opioids
New RCT shows Tylenol plus Ibuprofen works better than Vicodin
 • 
Noah Davis
"The change was immediate: I lost all desire to drink alcohol on Mounjaro."
From more than a dozen drinks a day to zero overnight.
 • 
Noah Davis
3
Can GLP-1s reduce crime? We are planning a study to find out.
A support plus GLP-1 study that confronts the cycle of addiction and incarceration amongst women.
 • 
Nick Horton
RFK Jr and MAHA, Alcohol, Soda, and Lung Cancer
Upstream, upstream, upstream
 • 
Nicholas Reville
© 2025 CASPR
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture